Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.62 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29692068 | 0.91 | NR1H4 (0.61) | NR1H4CYP3A4CYP2C8GPBAR1 | |
| SCHEMBL24599004 | 0.91 | NR1H4 (0.61) | NR1H4CYP3A4CYP2C8GPBAR1 | |
| SCHEMBL29692153 | 0.91 | NR1H4 (0.61) | NR1H4CYP3A4CYP2C8GPBAR1 | |
| SCHEMBL27192273 | 0.91 | NR1H4 (0.61) | NR1H4CYP3A4CYP2C8GPBAR1 | |
| SCHEMBL20031112 | 0.90 | NR1H4 (0.73) | NR1H4 | |
| SCHEMBL20031239 | 0.90 | NR1H4 (0.73) | NR1H4 | |
| SCHEMBL20031307 | 0.90 | NR1H4 (0.73) | NR1H4 | |
| SCHEMBL22578450 | 0.88 | NR1H4 (0.82) | NR1H4GPBAR1 | |
| SCHEMBL1096304 | 0.88 | NR1H4 (0.81) | NR1H4GPBAR1 | |
| SCHEMBL29692122 | 0.88 | NR1H4 (0.57) | NR1H4CYP3A4CYP2C8GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210244744-A1 | TREATING LIVER DISORDERS | Terns, Inc. | 2021-08-12 | — | — | US | claimed |
| CN-112771026-A | Treating liver disorders | 拓臻制药公司 | 2021-05-07 | — | — | CN | claimed |
| US-8153624-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | claimed |
| EP-2178851-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2011-12-28 | — | — | EP | claimed |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2010-06-17 | — | — | US | claimed |
| US-20210244744-A1 | TREATING LIVER DISORDERS | Terns, Inc. | 2021-08-12 | — | — | US | disclosed |
| CN-112771026-A | Treating liver disorders | 拓臻制药公司 | 2021-05-07 | — | — | CN | disclosed |
| EP-2178851-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2011-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210244744-A1 | TREATING LIVER DISORDERS | FABP1, CPT1A, GOT2 | NR1H4 19/4885CYP3A4 458/4885CYP2C8 232/4885 |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, FXR1, SLC10A1 | NR1H4 1/4885CYP3A4 494/4885CYP2C8 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.